Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 77

Sort by

Sort Order Select

Journal Articles

Retrospective Analysis of the Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin

Blood (2021) 138 (Supplement 1): 876.

https://doi.org/10.1182/blood-2021-145184

Published: 2021

Journal Articles

Replacing the Anthracycline By Gemtuzumab Ozogamicin in Older Patients with De Novo Standard-Risk Acute Myeloid Leukemia Treated Intensively - Results of the Randomized ALFA1401-Mylofrance 4 Study

Blood (2021) 138 (Supplement 1): 31.

https://doi.org/10.1182/blood-2021-145152

Published: 2021

Journal Articles

Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia

Blood (2020) 135 (8): 542–546.

https://doi.org/10.1182/blood.2019003471

Published: 2020

Includes: Supplemental data

Journal Articles

Acute Myeloid Leukemia and Antifungal Prophylaxis Era: Compliance of AML Centers, Invasive Fungal Infection (IFI) Classification, IFI Incidence and AML Outcomes from ALFA 2007- 02 Study

Blood (2019) 134 (Supplement_1): 2618.

https://doi.org/10.1182/blood-2019-130642

Published: 2019

Journal Articles

Outcomes Following Hematopoietic Stem Cell Transplantation in Patients Treated with Chemotherapy with or without Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

Cécile Pautas, Emmanuel Raffoux, MD, Juliette Lambert, Ollivier Legrand, MD PhD, Rebecca J Benner, Erik R. Vandendries, MD PhD, Karïn Gogat, Hervé Dombret, MD, Sylvie Castaigne, MD

Blood (2018) 132 (Supplement 1): 28.

https://doi.org/10.1182/blood-2018-99-111251

Published: 2018

Journal Articles

Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial

Blood (2017) 130 (Supplement 1): 889.

https://doi.org/10.1182/blood.V130.Suppl_1.889.889

Published: 2017

Journal Articles

Early Detection of WT1 minimal Residual Disease Predicts Outcome in Acute Myeloid Leukemia and Identify Patients with High Risk of Relapse Independently of Allogeneic Stem Cell Transplantation

Juliette Lambert, Jérôme Lambert, MDPhD, Xavier Thomas, MD, Alice Marceau-Renaut, PharmD, Aline Renneville, MDPhD, Marie-Magdelaine Coude, MD, Sandrine Hayette, MD, Christian Recher, MD PhD, Emmanuel Raffoux, MD, Arnaud Pigneux, MD PhD, Céline Berthon, MD PhD, Christine Terré, PharmD, PhD, Karine Celli-Lebras, CRA, Sylvie Castaigne, MD, Nicolas Boissel, MD PhD, Philippe Rousselot, Herve Dombret, MD, Claude Preudhomme, PharmD, PhD

Blood (2017) 130 (Supplement 1): 29.

https://doi.org/10.1182/blood.V130.Suppl_1.29.29

Published: 2017

Journal Articles

ABCA3 Expression Predicts Response to Gemtuzumab Ozogamicin in AML

Antony Ceraulo, Aminetou Mint-Mohamed, Delphine Maucort-Boulch, MD PhD, Etienne Paubelle, MD PhD, Xavier Thomas, MD PhD, Lea Herpe, Olivier Nibourel, PharmD, PhD, Claude Preudhomme, MD PhD, Sylvie Castaigne, MD PhD, Hervé Dombret, Eric Wattel, MD PhD

Blood (2016) 128 (22): 3946.

https://doi.org/10.1182/blood.V128.22.3946.3946

Published: 2016

Journal Articles

Age and Gemtuzumab Ozogamicin Influence the Prognostic Impact of TET2 Expression and Splicing in Intensively Treated Patients with Acute Myeloid Leukemia

Antony Ceraulo, Aminetou Mint-Mohamed, Delphine Maucort-Boulch, MD PhD, Helene Lapillone, Guy Leverger, MD, Etienne Paubelle, MD PhD, Xavier Thomas, MD PhD, Olivier Nibourel, PharmD, PhD, Claude Preudhomme, MD PhD, Sylvie Castaigne, MD PhD, Hervé Dombret, Lea Herpe, Christine Ragu, PhD, Yves Bertrand, MD PhD, Franck Mortreux, PhD, Eric Wattel, MD PhD

Blood (2016) 128 (22): 3952.

https://doi.org/10.1182/blood.V128.22.3952.3952

Published: 2016

Journal Articles

Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy. Prospective Observational Study from the Acute Leukemia French Association (ALFA) Group

Blood (2016) 128 (22): 3696.

https://doi.org/10.1182/blood.V128.22.3696.3696

Published: 2016

Journal Articles

Incidence and Risk Factors for Central Nervous System Relapse in Very Elderly Patients over 80 with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of Two Lysa Studies

Aurelie Cabannes-Hamy, MD, Frederic Peyrade, MD, Fabrice Jardin, MD PhD, Jean-Francois Emile, Sylvie Castaigne, MD PhD, Bertrand Coiffier, MD PhD, Corinne Haioun, MD, Aurore Perrot, MD, Olivier Fitoussi, MD, Safia Chebrek, Christophe Fruchart, Julie Abraham, MD, Richard Delarue, MD, Marc Andre, MD, Gilles Salles, MD PhD, Philippe Gaulard, MD PhD, Herve Tilly, MD PhD, Catherine Thieblemont, MD PhD

Blood (2016) 128 (22): 927.

https://doi.org/10.1182/blood.V128.22.927.927

Published: 2016

Journal Articles

Arsenic Trioxide (ATO) and ATRA with Limited Chemotherapy (CT) in Newly Diagnosed Standard Risk APL in the Elderly. a Report By the French Belgian Swiss APL Group (APL 2006 trial)

Lionel Ades, MD PhD, Xavier Thomas, MD PhD, Agnès Guerci, MD PhD, Arnaud Pigneux, MD, Norbert Vey, Emmanuel Raffoux, MD, Sylvie Castaigne, MD PhD, Olivier Spertini, Dominique Bron, MD PhD, Jean Pierre Marolleau, MD PhD, Gandhi Damaj, MD, Dominique Bordessoule, MD PhD, Julie Lejeune, Sylvie Chevret, Pierre Fenaux, MD PhD

Blood (2016) 128 (22): 898.

https://doi.org/10.1182/blood.V128.22.898.898

Published: 2016

Journal Articles

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia

Blood (2016) 127 (17): 2157–2160.

https://doi.org/10.1182/blood-2016-01-689976

Published: 2016

Includes: Supplemental data

Journal Articles

HFE Gene Mutation Status Predicts Response to Gemtuzumab Ozogamicin in AML

Etienne Paubelle, Alice Marceau, Florence Zylbersztejn, Mickael Dussiot, Ivan Cruz Moura, PhD, Pascale Cornillet-Lefebvre, MD, Jacques Delaunay, MD, Alan K. Burnett, Sylvie Castaigne, Philippe Guardiola, MD, Norbert Ifrah, MD PhD, Hervé Dombret, Claude Preudhomme, Robert K Hills, DPhil, Olivier Hermine

Blood (2015) 126 (23): 1307.

https://doi.org/10.1182/blood.V126.23.1307.1307

Published: 2015

Journal Articles

Correlation Between Bone Marrow Dysplasia and Genomic Profile in De Novo Acute Myeloid Leukemia (AML): A Study By the ALFA Group

Thomas Cluzeau, MDPhD, Orianne Wagner-Ballon, Thomas Boyer, Estelle Guerin, Emmanuel Benayoun, Daniel Lusina, Isabelle Garcia, Claude Gardin, Pierre Fenaux, MD PhD, Cecile Pautas, Bruno Quesnel, MD PhD, Dominique Bordessoule, Christine Terré, Xavier Thomas, MD PhD, Sylvie Castaigne, Aline Renneville, Claude Preudhomme, Herve Dombret, MD

Blood (2015) 126 (23): 2568.

https://doi.org/10.1182/blood.V126.23.2568.2568

Published: 2015

Journal Articles

Clofarabine-Based Consolidation Improves Relapse-Free Survival of Younger Adults with Non-Favorable Acute Myeloid Leukemia (AML) in First Remission: Results of the Randomized ALFA-0702/Clara Study (NCT 00932412)

Blood (2015) 126 (23): 218.

https://doi.org/10.1182/blood.V126.23.218.218

Published: 2015

Journal Articles

Final Analysis of the ALFA 0701 Study

Sylvie Castaigne, Cécile Pautas, Christine Terré, Aline Renneville, Claude Gardin, Felipe Suarez, MD PhD, Denis Caillot, MD, Céline Berthon, MD PhD, Philippe Rousselot, MD, Claude Preudhomme, PharmD, PhD, Laure Morisset, Karine Celli Lebras, Sylvie Chevret, MD PhD, Hervé Dombret, MD

Blood (2014) 124 (21): 376.

https://doi.org/10.1182/blood.V124.21.376.376

Published: 2014

Journal Articles

Prognostic Analysis of GATA2 Mutations in CEBPA -Mutated Acute Myeloid Leukemia

Alice Marceau-Renaut, Meyling Cheok, Nicolas Duployez, Olivier Nibourel, Nathalie Helevaut, Céline Rodriguez, Karine Celli-Lebras, Céline Berthon, Guy Leverger, MD, Nicolas Boissel, MD PhD, Christine Terré, Xavier Thomas, Sylvie Castaigne, Herve Dombret, Claude Preudhomme, PharmD, PhD, Aline Renneville

Blood (2014) 124 (21): 2360.

https://doi.org/10.1182/blood.V124.21.2360.2360

Published: 2014

Journal Articles

Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group

Blood (2014) 124 (21): 2327.

https://doi.org/10.1182/blood.V124.21.2327.2327

Published: 2014

Journal Articles

Absolute Quantification of EVI1 Overexpression in Acute Myeloid Leukemia By RQ-PCR Analysis : A Study of the ALFA Group

Thomas Smol, Aline Renneville, Olivier Nibourel, Alice Marceau-Renaut, Karine Celli-Lebras, Céline Berthon, Bruno Quesnel, MD PhD, Nicolas Boissel, MD PhD, Christine Terré, Xavier Thomas, Sylvie Castaigne, Hervé Dombret, MD PhD, Claude Preudhomme, PharmD, PhD

Blood (2014) 124 (21): 1062.

https://doi.org/10.1182/blood.V124.21.1062.1062

Published: 2014

NARROW

Retrospective Analysis of the Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin

Replacing the Anthracycline By Gemtuzumab Ozogamicin in Older Patients with De Novo Standard-Risk Acute Myeloid Leukemia Treated Intensively - Results of the Randomized ALFA1401-Mylofrance 4 Study

Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia

Acute Myeloid Leukemia and Antifungal Prophylaxis Era: Compliance of AML Centers, Invasive Fungal Infection (IFI) Classification, IFI Incidence and AML Outcomes from ALFA 2007- 02 Study

Outcomes Following Hematopoietic Stem Cell Transplantation in Patients Treated with Chemotherapy with or without Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial

Early Detection of WT1 minimal Residual Disease Predicts Outcome in Acute Myeloid Leukemia and Identify Patients with High Risk of Relapse Independently of Allogeneic Stem Cell Transplantation

ABCA3 Expression Predicts Response to Gemtuzumab Ozogamicin in AML

Age and Gemtuzumab Ozogamicin Influence the Prognostic Impact of TET2 Expression and Splicing in Intensively Treated Patients with Acute Myeloid Leukemia

Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy. Prospective Observational Study from the Acute Leukemia French Association (ALFA) Group

Incidence and Risk Factors for Central Nervous System Relapse in Very Elderly Patients over 80 with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of Two Lysa Studies

Arsenic Trioxide (ATO) and ATRA with Limited Chemotherapy (CT) in Newly Diagnosed Standard Risk APL in the Elderly. a Report By the French Belgian Swiss APL Group (APL 2006 trial)

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia

HFE Gene Mutation Status Predicts Response to Gemtuzumab Ozogamicin in AML

Correlation Between Bone Marrow Dysplasia and Genomic Profile in De Novo Acute Myeloid Leukemia (AML): A Study By the ALFA Group

Clofarabine-Based Consolidation Improves Relapse-Free Survival of Younger Adults with Non-Favorable Acute Myeloid Leukemia (AML) in First Remission: Results of the Randomized ALFA-0702/Clara Study (NCT 00932412)

Final Analysis of the ALFA 0701 Study

Prognostic Analysis of GATA2 Mutations in CEBPA -Mutated Acute Myeloid Leukemia

Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group

Absolute Quantification of EVI1 Overexpression in Acute Myeloid Leukemia By RQ-PCR Analysis : A Study of the ALFA Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only